An AI-assisted model based on 71 different blood proteins could help doctors better predict retinal degeneration in diabetic ...
An AI-assisted model based on 71 different blood proteins could help doctors better predict retinal degeneration in diabetic ...
Oculis Holding AG shares plunged >35% after both Phase 3 DIAMOND trials for OCS-01 in diabetic macular edema failed primary ...
Belite Bio, Inc (NASDAQ: BLTE) ('Belite Bio®” or the 'Company”), a clinical-stage drug development company focused on ...
Opus Genetics, Inc. (Nasdaq: IRD) ('Opus Genetics” or the 'Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with ...
European commercialization introduces an additional aflibercept biosimilar option for major retinal indications, potentially ...
Ocugen frames 2026 as pivotal because it expects meaningful milestones across all three core ocular programs in the same year ...
New research challenges concerns that tirzepatide harms the eyes, finding lower rates of diabetic retinopathy instead.
When approved, ONS-5010/LYTENAVA™ will be the first and only FDA-approved ophthalmic formulation of bevacizumab supported by standardized manufacturing, FDA-approved labeling, and robust ...
The Kingdom of Saudi Arabia is advancing a modern health model centred on innovative technologies, particularly artificial ...
Eye specialists say the eyes can often reveal early warning signs of both eye diseases and broader health conditions ...
RESEARCH TRIANGLE PARK, N.C., May 28, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results